Delivering on the promise of precision medicine, Loxo Oncology Inc.'s larotrectinib could be the first of a modern form of oncology drug development – facilitated by US FDA's breakthrough designation program.
Larotrectinib is a targeted therapy that selectively inhibits the tropomyosin receptor kinase (TRK) fusion protein and is one of the first attempts at molecularly defined patient